Vicore Pharma Q2 FY26 operating loss widens to SEK 150.1 million; loss per share deepens to SEK 0.51 - VCRE News | RalliesVicore Pharma Q2 FY26 operating loss widens to SEK 150.1 million; loss per share deepens to SEK 0.51
V
VCRE• ASPIRE Phase 2b enrollment completed
- Vicore said it completed ASPIRE Phase 2b enrollment in idiopathic pulmonary fibrosis (IPF), topping 360 patients across more than 100 sites.
- Topline results are expected mid-2027.
- The company also commenced Nasdaq U.S. trading in July under VCRE.
- CEO Ahmed Mousa said the quarter marked a shift toward executing for the readout.
Q2 operating loss widens as revenues rise
- Vicore Pharma Holding posted Q2 operating loss of SEK 150.1 million, widening 34.98% from a year earlier.
- Net revenues rose 29.41% to SEK 2.2 million; net loss widened 23.74% to SEK 142.8 million.
- Cash, cash equivalents, and short-term investments fell to SEK 905.6 million as of June 30 from SEK 1.17 billion at Dec. 31.
- Loss per share deepened to SEK 0.51.
•
